BOOSTING THE INNATE IMMUNE SYSTEM

Even with current vaccines, anti-virals and antibiotics significant unmet needs remain to better prevent and treat respiratory infections. Pulmotect technology has demonstrated activity and completed Phase I clinical trials to address these unmet needs.

COPD EXACERBATIONS

COPD, which includes chronic bronchitis and emphysema, affects more than 24 million Americans and is the third leading cause of death in the U.S.

Centers for Disease Control

EPIDEMIC AND EMERGING PATHOGENS

More than 2 billion people worldwide could be impacted by a pandemic. Despite remarkable advances in medical research and treatments during the 20th century, infectious diseases remain among the leading causes of death worldwide.

National Institute of Allergy and Infectious Disease

IMMUNOCOMPROMISED PATIENTS

Forecast sales for the immuno-stimulants market are estimated to reach $17.6 billion.

Our Product

Pulmotect’s lead product, PUL-042, is a clinically stage inhaled therapeutic that stimulates the innate immune system in minutes to provide immediate and effective protection that lasts for days against all major classes of pathogens.

Our Research

Two previously completed phase I clinical trials tested PUL-042’s safety and patient tolerance in healthy individuals, which showed an acceptable safety profile. Armed with FDA approval to begin a third trial, researchers are set to conduct a follow-up dosing study to establish the drug’s efficacy in stable, but immune-compromised cancer patients.

The Market

Pulmotect’s initial market focus is on the reduction of chronic obstructive pulmonary disease (COPD) exacerbations, which are characterized by an acute worsening of symptoms mostly precipitated by a bacterial or viral infection.